The Avastin-based therapy patient benefit is comparable in terms of PFS to sunitinib.

‘.. Avastin+ IFN has been shown to significantly increase the time patients with mRCC without their disease getting worse life. The Avastin-based therapy patient benefit is comparable in terms of PFS to sunitinib, but the treatment regimens have very different side effect profiles. – ‘Side effects are a very important aspect for physicians and patients consider when making treatment decisions, especially with new treatments, the long time without disease progression,’said Professor Gerald Mickisch from the Center of Operative Urology, Academic Hospital Bremen in Germany, and author of the study.

Observed no new or unexpected adverse events.. The results of AVOREN study showed that the addition of Avastin to IFN:- – progression-free survival was almost doubled from a median 5.4 to 10.2 months, response tumor significantly from 12.8 percent with IFN alone at 31 when Avastin was added – dose reduction of IFN did not affect the effectiveness of the combination with Avastin – The study also showed a trend towards improved survival, but full of survival data are expected during the second half of 2008.Hughes-Fulford also found to be flurbiprofen is, a non-steroidal anti-inflammatory drug to for arthritis, blocks the production of cPLA2 and broke the chain of of the cell growth. She says, that new drugs could designed that may be specifically cPLA2 and stop COX 2 are published before.